Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.72 |
| ▸ | HTT | P42858 | 1/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.72 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.54 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.54 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ILK | Q13418 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
| ▸ | TYR | P14679 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | AXL | P30530 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31298 | 0.84 | HTT (1.00) | GAAHTTL3MBTL1CA2PIK3CD | |
| Hydrochloric Acid SCHEMBL11729261 | 0.82 | HTT (0.96) | GAAHTTL3MBTL1CA2PIK3CD | |
| SCHEMBL2190447 | 0.79 | ALDH1A1 (0.61) | GAAHTTL3MBTL1PIK3CDPIK3CA | |
| SCHEMBL28090972 | 0.79 | CA2 (0.56) | GAAHTTL3MBTL1CA2SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL11236118 | 0.78 | ALDH1A1 (0.59) | GAAHTTL3MBTL1PIK3CDPIK3CA | |
| SCHEMBL482340 | 0.76 | LOXL2 (0.61) | GAAHTTL3MBTL1PIK3CDPIK3CA | |
| SCHEMBL21983970 | 0.76 | PIK3CA (0.54) | GAAHTTL3MBTL1PIK3CDPIK3CA | |
| SCHEMBL21412413 | 0.76 | CA2 (0.53) | GAAHTTL3MBTL1CA2SMN1; SMN2 | |
| SCHEMBL13244648 | 0.76 | PIK3CA (0.54) | GAAHTTL3MBTL1PIK3CDPIK3CA | |
| SCHEMBL12262 | 0.76 | MAPT (0.72) | GAAHTTL3MBTL1PIK3CDPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570648-B2 | 6,7-dihydro-5H-pyrido[2,3-c]pyridazine derivatives and related compounds as Bcl-xL protein inhibitors and pro-apoptotic agents for treating cancer | LES LABORATOIRES SERVIER (FR) | 2026-03-10 | — | — | US | disclosed |
| EP-4676480-A1 | INHIBITORS OF DNA POLYMERASE THETA | Breakpoint Therapeutics GmbH (DE) | 2026-01-14 | — | — | EP | disclosed |
| CN-120758004-A | Biodegradable polylactic acid plastic bag and preparation method thereof | 安庆市众友塑料包装有限公司 | 2025-10-10 | — | — | CN | disclosed |
| US-12162895-B2 | DNA polymerase theta inhibitor for treatment of cancer | BREAKPOINT THERAPEUTICS GMBH (DE) | 2024-12-10 | — | — | US | disclosed |
| US-20240391931-A1 | TRICYCLIC FUSED PYRIMIDINE COMPOUNDS FOR USE AS HER2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-11-28 | — | — | US | disclosed |
| US-12145945-B2 | Compounds, compositions, and therapeutic uses thereof | BREAKPOINT THERAPEUTICS GMBH (DE) | 2024-11-19 | — | — | US | disclosed |
| WO-2024230578-A1 | CYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2024-11-14 | — | — | WO | disclosed |
| US-20240336628-A1 | NOVEL COMPOUNDS, COMPOSITIONS, AND THERAPEUTIC USES THEREOF | BREAKPOINT THERAPEUTICS GMBH (DE) | 2024-10-10 | — | — | US | disclosed |
| US-20240327431-A1 | DNA POLYMERASE THETA INHIBITOR FOR TREATMENT OF CANCER | BREAKPOINT THERAPEUTICS GMBH (DE) | 2024-10-03 | — | — | US | disclosed |
| US-20240327430-A1 | NOVEL COMPOUNDS, COMPOSITIONS, AND THERAPEUTIC USES THEREOF | BREAKPOINT THERAPEUTICS GMBH (DE) | 2024-10-03 | — | — | US | disclosed |
| WO-2007109120-A2 | IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE | AMBIT BIOSCIENCES CORPORATION (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070093488-A1 | Novel Benzothiazoles And The Use Thereof As Medicaments | AVENTIS PHARMA S.A. (FR) | 2007-04-26 | — | — | US | disclosed |
| CN-1918128-A | Fused ring 4-oxo-pyrimidine derivatives | BANYU PHARMA CO LTD (JP) | 2007-02-21 | — | — | CN | disclosed |
| EP-1745044-A2 | BENZOTHIAZOLE DERIVATIVES HAVING CDK MODULATING ACTIVITY AND USE THEREOF AS ANTICANCER AGENTS | Aventis Pharma S.A. (FR) | 2007-01-24 | — | — | EP | disclosed |
| EP-1717230-A1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | disclosed |
| EP-1638954-A1 | FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS | AMGEN INC. (US) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005097787-A2 | NOVEL BENZOTHIAZOLES AND THE USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA S.A. (FR) | 2005-10-20 | — | — | WO | disclosed |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| US-20040209892-A1 | Heterocyclic compounds and methods of use | U.S. PATENT OPERATIONS | 2004-10-21 | — | — | US | disclosed |
| WO-2004085425-A1 | FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS | AMGEN INC (US) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12162895-B2 | DNA polymerase theta inhibitor for treatment of cancer | POLQ, POLB, POLH | GAA 265/4885HTT 2010/4885L3MBTL1 3891/4885 |
| US-20240327430-A1 | NOVEL COMPOUNDS, COMPOSITIONS, AND THERAPEUTIC USES THEREOF | POLQ, POLK, POLB | GAA 130/4885HTT 1980/4885L3MBTL1 4408/4885 |
| US-20240391931-A1 | TRICYCLIC FUSED PYRIMIDINE COMPOUNDS FOR USE AS HER2 INHIBITORS | ERBB2, ERBB3, EGFR | GAA 945/4885HTT 2542/4885L3MBTL1 4314/4885 |
| US-20070093488-A1 | Novel Benzothiazoles And The Use Thereof As Medicaments | TFEB, ABAT, BRD4 | GAA 960/4885HTT 1653/4885L3MBTL1 4287/4885 |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | HRH4, HRH2, HRH3 | GAA 3777/4885HTT 1066/4885L3MBTL1 2929/4885 |
| US-12570648-B2 | 6,7-dihydro-5H-pyrido[2,3-c]pyridazine derivatives and related compounds as Bcl-xL protein inhibitors and pro-apoptotic agents for treating cancer | BCOR, BCL2A1, BAK1 | GAA 4749/4885HTT 4455/4885L3MBTL1 1905/4885 |
| US-20240336628-A1 | NOVEL COMPOUNDS, COMPOSITIONS, AND THERAPEUTIC USES THEREOF | POLQ, POLK, POLB | GAA 130/4885HTT 1980/4885L3MBTL1 4408/4885 |
| US-20040209892-A1 | Heterocyclic compounds and methods of use | VHL, NQO1, HPGDS | GAA 172/4885HTT 1040/4885L3MBTL1 2836/4885 |
| US-20240327431-A1 | DNA POLYMERASE THETA INHIBITOR FOR TREATMENT OF CANCER | POLQ, POLB, POLH | GAA 265/4885HTT 2010/4885L3MBTL1 3891/4885 |
| US-12145945-B2 | Compounds, compositions, and therapeutic uses thereof | POLQ, POLK, POLB | GAA 118/4885HTT 1920/4885L3MBTL1 4341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.